Effectiveness of Somatostatin Analogues in patients with Gastric antral vascular ectasia and symptomatic gastrointestinal bleeding: SAGAVE-Pilot study - SAGAVE-Pilot study

Radboudumc0 个研究点目标入组 12 人开始时间: 2021年1月21日最近更新: 2021年4月5日

适应症

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方: Radboudumc
入组人数: 12

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•In order to be eligible to participate in this study, a subject must meet all of the following criteria:
•- Patients older than 18 years with written informed consent.
•- Endoscopic diagnosis of GAVE, confirmed within the last 12 months
•- Endoscopic refractory: at least 1 endoscopic APC, RFA, or other treatment modality performed within 12 months OR unable to receive endoscopic treatment (e.g. Pacemaker, ICD) OR patient has repeatedly indicated that they do not want endoscopic treatment OR treating physician had deemed further endoscopic treatment not relevant
•- Substantial transfusion dependency: at least 4 blood units and / or intravenous iron in the 6 months prior to study inclusion with:
•? At least one serum ferritin below < 30 ug/l within the last 6 months requiring iron infusion above or equal to 1 g and/or
•? Haemoglobin below 5.6 mmol/l (9.0 g/dl) or are in need of transfusions due to anaemia related symptoms within the last 6 months requiring red blood cell transfusion above.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 2
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 10

排除标准

•A potential subject who meets any of the following criteria will be excluded from participation in this study:
•- Insulinoma
•- Uncontrolled diabetes mellitus as defined by HbA1c >64 mmol/ml, despite adequate therapy,
•- Symptomatic cholecystolithiasis (possible side effect octreotide),
•- Pregnancy or nursing women or women have a pregnancy wish during the study period.
•- Liver cirrhosis Child-Pugh C
•- Chronic or acute pancreatitis
•- Patients with other plausible causes of gastrointestinal bleeding (e.g. severe portal hypertensive gastropathy and oesophageal varices which have recently bled)
•- Bradycardia (heart rate below 50)*
•- Hypersensitivity to the active ingredient (octreotide) or to auxiliary materials of the study medication
•- Severe diseases / comorbidities with a life expectancy < 1 year
•- Use of other anti-angiogenic drug treatment (thalidomide and / or bevacizumab)
•*If a patient has a heart rate below 60 and uses cardiovascular medication that affect the heart rate (e.g. beta blockers and calcium channel blockers) the prescribing specialist (or another competent specialist) will be consulted about the possibility to adjust the dose of these medicines. Patients with a heartrate below 50 (despite dose adjustments) will be excluded from participation.
•The endoscopic appearance of diffuse-pattern GAVE can be similar to portal hypertensive gastropathy (PHG). An important difference is that PHG only occurs in patients with portal hypertension. A patient with portal hypertension and no clear endoscopic distinction between both disorders cannot be included, unless a biopsy has been taken to confirm the diagnosis.

研究者

发起方

Radboudumc

相似试验

招募中

不适用

Effectiveness of Somatostatin Analogues in patients with Gastric Antral Vascular Ectasia and symptomatic gastrointestinal bleeding: SAGAVE Pilot study

NL-OMON21472Radboudumc12

招募中

2 期

Effectiveness of Somatostatin Analogues in patients with Gastric antral vascular ectasia and symptomatic gastrointestinal bleeding: SAGAVE-trial1) Gastric Antral Vascular Ectasia. 2) Watermelon stomach.10017959

NL-OMON49336Radboud Universitair Medisch Centrum14

进行中（未招募）

1 期

The effectiveness of Octreotide in hereditary hemorrhagic telangiectasia (a.k.a. Rendu-Osler-Weber disease) patients who suffer from gastrointestinal bleeding.

EUCTR2018-004179-11-NLRadboudumc38

尚未招募

不适用

Onderzoek naar de effectiviteit van octreotide in hereditary hemorrhagic telangiectasia patiënten metdaarbij gastrointestinale bloedingen.

NL-OMON25382Radboudumc38

进行中（未招募）

1 期

The effectiveness of Octreotide in hereditary hemorrhagic telangiectasia(a.k.a. Rendu-Osler-Weber disease) patients who suffer fromgastrointestinal bleeding.

EUCTR2018-004179-11-DERadboudumc38